Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of K-877-ER and CSG452 alone or in combination for noncirrhotic NASH with fibrosis
jRCT2031230056Phase 2Completed
- Sponsor
- Kowa Research Institute, Inc.
- Start
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of pemafibrate and tofogliflozin in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Kowa Research Institute, Inc. Primary endpoint: Histologic improvement in disease activity without worsening of fibrosis at Week 48. Started Aug 2023; status: completed.
02
Drugs
pemafibratetofogliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2031230056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230056.